[144] Aura Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

AURA Form 144 notice reports a proposed sale of 7,722 common shares acquired by stock option exercise on 08/18/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $51,750.53 based on the filing. The filing states there were 62,119,873 shares outstanding at the time. No other securities were reported sold in the prior three months and payment for the acquired shares was in cash.

Positive

• Full Rule 144 disclosure provided including acquisition method, broker, and aggregate market value
• Sale size is small relative to outstanding shares (7,722 vs 62,119,873), indicating limited market impact

Negative

• Insider is selling shares, which some investors may interpret negatively despite immaterial size
• No context on insider role or holding post-sale is provided in the filing

Insights

Financial Analyst

TL;DR Routine insider sale from option exercise totaling 7,722 shares, small relative to outstanding shares.

The filing documents a controlled sale of shares acquired via stock option exercise on 08/18/2025. At an aggregate value of $51,750.53, the transaction is immaterial versus the reported 62,119,873 shares outstanding, indicating limited direct impact on share supply or company capitalization. This disclosure is standard and satisfies Rule 144 notice requirements.

Corporate Governance Expert

TL;DR Compliance-oriented filing showing insider sale; provides transparency but no material governance signal.

The Form 144 confirms the seller represents they possess no undisclosed material adverse information and that the sale will be routed through Morgan Stanley Smith Barney LLC. The notice includes the acquisition method (option exercise) and payment in cash, aligning with standard disclosure practices. Absence of additional sales in the prior three months reduces concerns about pattern selling.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7722	51750.53	62119873	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2025	Stock Option Exercise	Issuer			7722	08/18/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Aura Biosciences (AURA) report in this Form 144?

The Form 144 reports a proposed sale of 7,722 common shares acquired by stock option exercise on 08/18/2025 with an aggregate market value of $51,750.53.

Through which broker will the AURA shares be sold?

The filing states the broker as Morgan Stanley Smith Barney LLC located at 1 New York Plaza, New York, NY.

How many Aura shares were outstanding according to the filing?

The filing lists 62,119,873 shares outstanding.

Was payment for the acquired securities made in cash?

Yes. The filing indicates the shares were acquired by option exercise and payment was made in cash on 08/18/2025.

Did the filer report other sales in the past three months?

The filing states Nothing to Report for securities sold during the past three months.